130 related articles for article (PubMed ID: 6608139)
1. Effectiveness of pentostatin (2'-deoxycoformycin) in refractory lymphoid neoplasms.
Spiers AS; Ruckdeschel JC; Horton J
Scand J Haematol; 1984 Feb; 32(2):130-4. PubMed ID: 6608139
[TBL] [Abstract][Full Text] [Related]
2. 2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.
O'Dwyer PJ; Wagner B; Leyland-Jones B; Wittes RE; Cheson BD; Hoth DF
Ann Intern Med; 1988 May; 108(5):733-43. PubMed ID: 3282467
[TBL] [Abstract][Full Text] [Related]
3. The role of pentostatin (2'-deoxycoformycin, dCF) in the management of lymphoproliferative malignancies.
Spiers AS
Blood Rev; 1987 Jun; 1(2):106-10. PubMed ID: 3332090
[TBL] [Abstract][Full Text] [Related]
4. Association of severe and fatal infections and treatment with pentostatin.
O'Dwyer PJ; Spiers AS; Marsoni S
Cancer Treat Rep; 1986 Sep; 70(9):1117-20. PubMed ID: 3488805
[TBL] [Abstract][Full Text] [Related]
5. Deoxycoformycin in therapy of refractory lymphoid neoplasms.
Ho AD; Thaler J; Kuse R; Willemze R; Mandelli F; Lauria F; Zittoun R; Stryckmans P
Onkologie; 1988 Feb; 11(1):35-7. PubMed ID: 3283623
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of deoxycoformycin.
Major PP; Agarwal RP; Kufe DW
Blood; 1981 Jul; 58(1):91-6. PubMed ID: 6263381
[TBL] [Abstract][Full Text] [Related]
7. An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma.
Grever MR; Bisaccia E; Scarborough DA; Metz EN; Neidhart JA
Blood; 1983 Feb; 61(2):279-82. PubMed ID: 6600401
[TBL] [Abstract][Full Text] [Related]
8. Successful chemotherapy with deoxycoformycin in adult T-cell lymphoma-leukaemia.
Daenen S; Rojer RA; Smit JW; Halie MR; Nieweg HO
Br J Haematol; 1984 Dec; 58(4):723-7. PubMed ID: 6097297
[TBL] [Abstract][Full Text] [Related]
9. The activity of deoxycoformycin (pentostatin) in refractory leukemias and lymphomas.
Spiers AS
Ann N Y Acad Sci; 1985; 451():138-41. PubMed ID: 3878115
[No Abstract] [Full Text] [Related]
10. Deoxycoformycin in the treatment of leukemias and lymphomas.
Smyth JF; Prentice HG; Proctor S; Hoffbrand AV
Ann N Y Acad Sci; 1985; 451():123-8. PubMed ID: 3878113
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.
Prentice HG; Russell NH; Lee N; Ganeshaguru K; Blacklock H; Piga A; Smyth JF; Hoffbrand AV
Lancet; 1981 Dec; 2(8258):1250-4. PubMed ID: 6118669
[TBL] [Abstract][Full Text] [Related]
12. Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.
Yamaguchi K; Yul LS; Oda T; Maeda Y; Ishii M; Fujita K; Kagiyama S; Nagai K; Suzuki H; Takatsuki K
Leuk Res; 1986; 10(8):989-93. PubMed ID: 3489140
[TBL] [Abstract][Full Text] [Related]
13. The treatment of hairy-cell leukaemia with 2'-deoxycoformycin.
Johnston JB; Glazer RI; Pugh L; Israels LG
Br J Haematol; 1986 Jul; 63(3):525-34. PubMed ID: 3488071
[TBL] [Abstract][Full Text] [Related]
14. Treatment of cutaneous T cell lymphoma with 2'-deoxycoformycin (pentostatin).
Dang-Vu AP; Olsen EA; Vollmer RT; Greenberg ML; Hershfield MS
J Am Acad Dermatol; 1988 Oct; 19(4):692-8. PubMed ID: 3263401
[TBL] [Abstract][Full Text] [Related]
15. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
[TBL] [Abstract][Full Text] [Related]
16. Biochemical consequences of 2'-deoxycoformycin treatment in a patient with T-cell lymphoma. Some unusual findings.
de Korte D; Haverkort WA; van Leeuwen EF; Roos D; van Gennip AH
Cancer; 1987 Aug; 60(4):750-5. PubMed ID: 3496148
[TBL] [Abstract][Full Text] [Related]
17. Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.
Ho AD; Thaler J; Willemze R; Lauria F; Derossi G; Kuse R; Stryckmans P; Blanc CM; Cataldo F; McVie G
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():60-2. PubMed ID: 2653520
[TBL] [Abstract][Full Text] [Related]
18. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia.
Urba WJ; Baseler MW; Kopp WC; Steis RG; Clark JW; Smith JW; Coggin DL; Longo DL
Blood; 1989 Jan; 73(1):38-46. PubMed ID: 2783373
[TBL] [Abstract][Full Text] [Related]
19. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Ho AD; Thaler J; Mandelli F; Lauria F; Zittoun R; Willemze R; McVie G; Marmont AM; Prümmer O; Stryckmans P
J Clin Oncol; 1989 Oct; 7(10):1533-8. PubMed ID: 2789273
[TBL] [Abstract][Full Text] [Related]
20. Membrane phenotype and response to deoxycoformycin in mature T cell malignancies.
Dearden CE; Matutes E; Hoffbrand AV; Ganeshaguru K; Brozovic M; Williams HJ; Traub N; Mills M; Linch DC; Catovsky D
Br Med J (Clin Res Ed); 1987 Oct; 295(6603):873-5. PubMed ID: 2890401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
